Decorin suppresses bone metastasis in a breast cancer cell line

Oncology

Volumn 77, Issue 2, 2008, Pages 92-99

  Araki, Kentaro ^a   Wakabayashi, Hiroki ^a   Shintani, Ken ^a   Morikawa, Joji ^a   Matsumine, Akihiko ^a   Kusuzaki, Katsuyuki ^a   Sudo, Akihiro ^a   Uchida, Atsumasa ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Breast cancer; Decorin; MDA MB 231; Osteolytic bone metastasis

Indexed keywords

DECORIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL MOTILITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE THERAPY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOLYSIS; PROTEOGLYCANS;

EID: 67649863505     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228253     Document Type: Article

References (36)

1. Reed CC, Iozzo RV: The role of decorin in collagen fibrillogenesis and skin homeosta-sis. Glycoconj J 2002; 19: 249-255.
2. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802. (Pubitemid 41215488)
3. Mercadante S: Malignant bone pain: patho-physiology and treatment. Pain 1997; 69: 1-18.
4. Troup S, Njue C, Kliewer EV, Parisien M, Ro-skelley C, Chakravarti S, Roughley PJ, Murphy LC, Watson PH: Reduced expression of the small leucine-rich proteoglycans, lumi-can, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 2003; 9: 207-214.
5. Tralhao JG, Schaefer L, Micegova M, Evaris-to C, Schonherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H, Lemarchand P: In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. Faseb J 2003; 17: 464-466.
6. Shintani K, Matsumine A, Kusuzaki K, Mo-rikawa J, Matsubara T, Wakabayashi T, Ara-ki K, Satonaka S, Wakabayashi H, Iino T, Uchida A: Decorin supresses lung metastasis of murine osteosarcome. Oncol Rep 2008; 19: 1533-1539.
7. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL: Ge-nomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 2005; 3: 1-13.
8. Humphrey MB, Daws MR, Spusta SC, Niemi EC, Torchia JA, Lanier LL, Seaman WE, Na-kamura MC: TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res 2006; 21: 237-245.
9. Humphrey MB, Ogasawara K, Yao W, Spusta SC, Daws MR, Lane NE, Lanier LL, Naka-mura MC: The signaling adapter protein DAP12 regulates multinucleation during os-teoclast development. J Bone Miner Res 2004; 19: 224-234.
10. Hiraga T, Nakajima T, Ozawa H: Bone resorption induced by a metastatic human melanoma cell line. Bone 1995; 16: 349-356.
11. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR, Sun LZ: Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. Cancer Res 2006; 66: 6714-6721.
12. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces met-astatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55: 3551-3557.
13. Grover J, Chen XN, Korenberg JR, Roughley PJ: The human lumican gene. Organization, chromosomal location, and expression in ar-ticular cartilage. J Biol Chem 1995; 270: 21942-21949.
14. Leygue E, Snell L, Dotzlaw H, Troup S, Hil-ler-Hitchcock T, Murphy LC, Roughley PJ, Watson PH: Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol 2000; 192: 313-320.
15. Henderson BE, Ross RK, Pike MC: Hormonal chemoprevention of cancer in women. Science 1993; 259: 633-638.
16. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
17. Ishizawar R, Parsons SJ: c-Src and cooperating partners in human cancer. Cancer Cell 2004; 6: 209-214.
18. Yoneda T, Sasaki A, Mundy GR: Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994; 32: 73-84. (Pubitemid 24322250)
19. Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
20. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593.
21. Yoneda T, Hiraga T: Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Com-mun 2005; 328: 679-687.
22. Green JR, Clezardin P: Mechanisms of bis-phosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002; 25(suppl 1):S3-S9.
23. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98: 1544-1549.
24. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T: Actions of bisphos-phonate on bone metastasis in animal models of breast carcinoma. Cancer 2000; 88 (suppl):2979-2988.
25. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M: Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepha-rose. J Biol Chem 1986; 261: 12665-12674.
26. Pfeilschifter J, Mundy GR: Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987; 84: 2024-2028.
27. Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101.
28. Yamaguchi Y, Mann DM, Ruoslahti E: Negative regulation of transforming growth factor- β by the proteoglycan decorin. Nature 1990; 346: 281-284.
29. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418-423.
30. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR: Transforming growth factor- β1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 1998; 75: 721-730. (Pubitemid 28145819)
31. Tong GM, Rajah TT, Zang XP, Pento JT: The effect of antiestrogens on TGF-β-mediated chemotaxis of human breast cancer cells. Anticancer Res 2002; 22(1A):103-106.
32. Zheng Q, Safina A, Bakin AV: Role of high-molecular weight tropomyosins in TGF-β-mediated control of cell motility. Int J Cancer 2008; 122: 78-90.
33. Reed CC, Gauldie J, Iozzo RV: Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 2002; 21: 3688-3695.
34. Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG, Lowenstein PR: Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 2004; 11: 721-732.
35. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, Iozzo RV: Decorin prevents metastatic spreading of breast cancer. Oncogene 2005; 24: 1104-1110.
36. Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B: Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004; 10: 5342-5348.